{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:19:50Z","timestamp":1793380790794,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clinthera.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T17:30:40Z","timestamp":1613669440000},"page":"297-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ethical and Regulatory Considerations of Placental Therapeutics"],"prefix":"10.1016","volume":"43","author":[{"given":"Anna L.","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.003_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/hum.2019.197","article-title":"Public acceptability of gene therapy and gene editing for human use: a systematic review","volume":"31","author":"Delhove","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.clinthera.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/uog.13190","article-title":"Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE)","volume":"42","author":"Lees","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMp1104409","article-title":"The long-term effects of in utero exposures \u2014 the DES story","volume":"364","author":"Goodman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2016.12.007","article-title":"Ethical dimensions of the fetus as a patient","volume":"43","author":"Chervenak","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10","key":"10.1016\/j.clinthera.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ogrm.2009.06.002","article-title":"Placental gene therapy","volume":"19","author":"David","year":"2009","journal-title":"Obstet Gynaecol Reprod Med"},{"key":"10.1016\/j.clinthera.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/uog.15880","article-title":"Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction","volume":"47","author":"Sheppard","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.placenta.2017.09.011","article-title":"Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction","volume":"59","author":"David","year":"2017","journal-title":"Placenta"},{"key":"10.1016\/j.clinthera.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/humc.2015.2523","article-title":"Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction? (EVERREST)","volume":"26","author":"Gancberg","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.clinthera.2021.01.003_bib9","first-page":"1","article-title":"The legal frameworks that govern fetal surgery in the United Kingdom, European union and the United States","author":"Cao","year":"2018","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.clinthera.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11019-019-09919-1","article-title":"Paternal consent in prenatal research: ethical aspects","volume":"23","author":"Johansson","year":"2020","journal-title":"Med Heal Care Philos"},{"key":"10.1016\/j.clinthera.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/14767058.2011.557791","article-title":"Drug development in preeclampsia: a \u2018no go\u2019 area?","volume":"25","author":"Everett","year":"2012","journal-title":"J\u00a0Matern Neonatal Med"},{"issue":"4","key":"10.1016\/j.clinthera.2021.01.003_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/AOG.0b013e3181d53843","article-title":"Food and Drug Administration drug approval: slow advances in obstetric care in the United States","volume":"115","author":"Wing","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib13","article-title":"Scientific impact paper No. 50. Developing new pharmaceutical treatments for obstetric conditions","volume":"31","author":"David","year":"2015","journal-title":"R\u00a0Coll Obstet Gynaecol - Guidel No"},{"issue":"11","key":"10.1016\/j.clinthera.2021.01.003_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002161","article-title":"Improving the pipeline for developing and testing pharmacological treatments in pregnancy","volume":"13","author":"Chappell","year":"2016","journal-title":"PLOS Med"},{"key":"10.1016\/j.clinthera.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1371\/journal.pmed.0050022","article-title":"Market failure and the poverty of new drugs in maternal health","volume":"5","author":"Fisk","year":"2008","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2021.01.003_bib16","series-title":"21CFR Part 316 - Orphan Drugs","year":"1983"},{"issue":"1","key":"10.1016\/j.clinthera.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.3.1","article-title":"The current status of orphan drug development\u00a0in Europe and the US","volume":"3","author":"Hall","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.clinthera.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.drudis.2012.08.009","article-title":"Orphan drugs: the regulatory environment","volume":"18","author":"Franco","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2021.01.003_bib19","unstructured":"European Medicines Agency. Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products [Internet]. Accessed 5 January 2021. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32000R0141."},{"key":"10.1016\/j.clinthera.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib21","series-title":"Points to Consider on the Estimation and Reporting on the Prevalence of a Condition for the Purpose of Orphan Designation","year":"2019"},{"key":"10.1016\/j.clinthera.2021.01.003_bib22","series-title":"Designating an Orphan Product: Drugs and Biological Products","year":"2020"},{"key":"10.1016\/j.clinthera.2021.01.003_bib23","series-title":"The Portal for Rare Diseases and Orphan Drugs. Preeclampsia Disease Definition","year":"2021"},{"key":"10.1016\/j.clinthera.2021.01.003_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/1471-0528.15590","article-title":"Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe","volume":"126","author":"Spencer","year":"2018","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib25","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2013.02.007","article-title":"Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study","volume":"208","author":"Unterscheider","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1471-0528.2008.01670.x","article-title":"Predictiveness of antenatal umbilical artery Doppler for adverse pregnancy outcome in small-for-gestational-age babies according to customised birthweight centiles: population-based study","volume":"115","author":"Figueras","year":"2008","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib27","series-title":"Acceptability of in Utero Hematopoietic Cell Transplantation for Sickle Cell Disease","first-page":"914","author":"Antiel","year":"2017"},{"key":"10.1016\/j.clinthera.2021.01.003_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41431-019-0387-4","article-title":"Stakeholder views and attitudes towards prenatal and postnatal transplantation of fetal mesenchymal stem cells to treat Osteogenesis Imperfecta","volume":"27","author":"Hill","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clinthera.2021.01.003_bib29","first-page":"96","article-title":"Pregnant women's experiences and perceptions of participating in the EVERREST Prospective Observational Study","volume":"125","author":"Harvey","year":"2018","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.clinthera.2021.01.003_bib30","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/JOE-17-0185","article-title":"Treating the dysfunctional placenta","volume":"234","author":"Sibley","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/hum.2016.046","article-title":"Maternal therapy with Ad.VEGF-A 165 increases fetal weight at term in a Guinea-pig model of fetal growth restriction","volume":"27","author":"Swanson","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.clinthera.2021.01.003_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2021.01.003_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4939-7498-6_14","article-title":"Simulation, therapeutic pharmacokinetics and analysis of off-target effects","volume":"1710","author":"Brownbill","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/humc.2017.090","article-title":"In\u00a0vitro human placental studies to support adenovirus-mediated VEGF-D \u0394N\u0394C maternal gene therapy for the treatment of severe early-onset fetal growth restriction","volume":"29","author":"Desforges","year":"2018","journal-title":"Hum Gene Ther Clin Dev [Internet]"},{"key":"10.1016\/j.clinthera.2021.01.003_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40778-018-0118-8","article-title":"Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy","volume":"4","author":"Sagar","year":"2018","journal-title":"Curr Stem Cel Rep"},{"key":"10.1016\/j.clinthera.2021.01.003_bib36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.ymthe.2020.10.012","article-title":"Fetal and maternal safety considerations for in utero therapy clinical trials: iFeTiS consensus statement","volume":"28","author":"Sagar","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2021.01.003_bib37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/archdischild-2019-317399","article-title":"Development of a neonatal adverse event severity scale through a Delphi consensus approach","volume":"104","author":"Salaets","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinthera.2021.01.003_bib38","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.01.003_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/uog.20422","article-title":"Development and validation of predictive models for QUiPP App v.2: tool for predicting preterm birth in women with symptoms of threatened preterm labor","volume":"55","author":"Carter","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.01.003_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12884-017-1226-7","article-title":"EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction","volume":"17","author":"Spencer","year":"2017","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:37Z","timestamp":1758963217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0149291821000059"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethical and Regulatory Considerations of Placental Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}